Scotland Says No To Novartis’ Piqray
Executive Summary
Scotland’s health technology assessment body, the SMC, has rejected Novartis’ targeted breast cancer drug Piqray, but accepted Lilly’s Verzenio, also for breast cancer.
You may also be interested in...
Scottish HTA Nod For Keytruda In Endometrial Carcinoma Marks UK First
Scotland has approved reimbursement for MSD’s Keytruda in combination with Eisai’s Lenvima for endometrial carcinoma. Meanwhile, a recommendation in England has been delayed.
England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios
Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.
Vision Loss Drug Vabysmo Secures English Funding; Oxlumo & Tavneos Deemed Too Pricey
Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.